Formidable ETF

George W. Lloyd sold 135,426 shares of Royalty Pharma

Canaccord Genuity Analyst Maintains Buy Rating for Pan American Silver

Flux Power released FY2026 Q1 earnings on November 13 After-Market EST, actual revenue USD 13.18 M (forecast USD 14.11 M), actual EPS USD -0.1521 (forecast USD -0.0666)

Flux Power Holdings Cuts 20% of Staff to Achieve Growth and Cost Reduction

Alliance Resource Partners LP Participates in AllianceBernstein Energy and Natural Resources Research Group Discussion

BofA Securities Analyst Gives Pan American Silver a Buy Rating with a $50 Price Target

Pan American Silver released FY2025 9 Months Earnings on November 12 After-Market EST, actual revenue USD 2.44 B, actual EPS USD 1.4254

Pan American Silver released FY2025 Q3 earnings on November 12, 2025, after-market EST, with forecast revenue of USD 846.77 M and forecast EPS of USD 0.57, but actual values were not disclosed.

Pan American Silver reports Q3 adjusted EPS of $0.48

Pan American Silver IBD Relative Strength Rating Upgraded

Royalty Pharma releases Q3 2025 earnings call transcript

Scotiabank Analyst Reiterates Buy Rating on Brookfield Infrastructure

DJE Kapital AG Increased Holdings in Pan American Silver

Brookfield Infrastructure released FY2025 9 Months Earnings on November 7 (EST), with actual revenue of USD 16.8 B and EPS of USD 0.4423

Brookfield Infrastructure released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 5.975 B (forecast USD 1.979 B), actual EPS USD 0.4554 (forecast USD -0.3368)

Brookfield Reports Significant Q3 Net Income Growth and Asset Sale

Genpact released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 1.291 B (forecast USD 1.266 B), actual EPS USD 0.83 (forecast USD 0.7686)

Genpact released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 3.761 B and EPS of USD 2.31

Flux Power to release FY2026 Q1 earnings on November 13 After-Market EST, forecast revenue USD 14.11 M, EPS USD -0.0766

Acacia Research released FY2025 Q3 earnings on November 5 Pre-Market (EST), actual revenue USD 59.45 M (forecast USD 38 M), actual EPS USD -0.03 (forecast USD -0.15)

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

Foxx Development

Palatin Tech

Mobile-Health Network Solutions

Nuvve

Datavault AI

CCSC Tech

Iveda Solutions

Harrison Global

Alps

RPRX

05:06 PM EST, 11/21/2025 (MT Newswires) -- George W. Lloyd, Executive Vice President, Investments & Chief Legal Officer, on November 19, 2025, sold 135,426 shares in Royalty Pharma ( RPRX ) for $5,192,656. Following the Form 4 filing with the SEC, Lloyd has control over a total of 993,831 Class A ordinary shares of the company, with 993,831 controlled indirectly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Royalty Pharma PLC - CL

Royalty Pharma Insider Sold Shares Worth $5,192,656, According to a Recent SEC Filing

George W. Lloyd, EVP of Royalty Pharma, reported the sale of common shares of the company. The information was published via EDGAR by Royalty Pharma on November 21, 2025. This brief was created by Public Technologies using AI and is for informational purposes only.

Reuters

Royalty Pharma EVP George W. Lloyd Reports Sale of Common Shares

GWL 2023 G HoldCo LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 52,426 shares. The sale is executed under a prearranged trading plan (10b5-1) and must occur within 90 days of filing. Goldman Sachs & Co is the broker for this transaction.

Shareholder GWL 2023 G HoldCo LLC Files To Sell 52,426 Of Royalty Pharma PLC [RPRX]

GWL 2020 G LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 52,000 shares on November 19, 2025, through Goldman Sachs & Co. This sale is executed under a prearranged trading plan (10b5-1).

Shareholder GWL 2020 G LLC Files To Sell 52,000 Of Royalty Pharma PLC [RPRX]

Royalty Pharma Insider Sold Shares Worth $2,735,329, According to a Recent SEC Filing

marketscreener

Royalty Pharma Insider Sold Shares Worth $2,735,329, According to a Recent SEC Filing

CFO Coyne Terrance P of Royalty Pharma PLC sold 69,594 shares worth $2.7 million, as disclosed in a Form 4 filed with the SEC. The sale was executed under a prearranged trading plan (10b5-1). Coyne's ending holdings are 829,306 shares. The Washington Service offers insider trading analysis and data services.

CFO Coyne Sells 69,594 ($2.7M) Of Royalty Pharma PLC [RPRX]

TPC RP 2021 LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 65,844 shares on November 17, 2025, through Goldman Sachs & Co. This sale is executed under a prearranged trading plan (10b5-1).

Shareholder TPC RP 2021 LLC Files To Sell 65,844 Of Royalty Pharma PLC [RPRX]

TPC RP EPA1 LLC, a shareholder of Royalty Pharma PLC, filed a Form 144 with the SEC to sell 3,750 restricted shares on November 17, 2025, through Goldman Sachs & Co. This sale is executed under a prearranged trading plan (10b5-1).

Shareholder TPC RP EPA1 LLC Files To Sell 3,750 Of Royalty Pharma PLC [RPRX]

Royalty Pharma reported Q3 2025 revenue of $609.29 million, raising its full-year guidance to $3.20-$3.25 billion. The company is also conducting a share repurchase program, buying back over 8% of shares in 2025. Despite improved revenue guidance, risks remain due to concentrated asset exposure. The company's narrative projects $4.0 billion in revenue and $922.7 million in earnings by 2028, requiring 20% annual growth. Fair value estimates vary, with potential upside but also risks from key asset underperformance.

Simplywall

Raised Revenue Guidance and Buybacks Might Change the Case for Investing in Royalty Pharma (RPRX)

Royalty Pharma plc has released the transcript of its Q3 2025 earnings call, held on November 5, 2025. Key executives discussed the company's financial results and strategic priorities, emphasizing non-GAAP liquidity measures for transparency. Analysts from major firms participated, and management highlighted the risks associated with forward-looking statements. The full transcript is available on the company's website, and attendees were advised to review the latest 10-K filing for risk factors.

Royalty Pharma plc Publishes Transcript of Q3 2025 Earnings Call